ArticleBMC pharmacology & toxicology2014
Hypersensitivity to oxaliplatin: clinical features and risk factors.
Article in BMC pharmacology & toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.
- Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients.International journal of clinical oncology · 2021Pooled it
- Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology/NSABP R04.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Trial
- A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.Drug design, development and therapy · 2015Trial
- Article
- Best available evidence for the management of oxaliplatin-induced hypersensitivity reactions, with implications for hepatic arterial infusion chemotherapy (HAIC).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- High-dose dexamethasone and prolonged infusion time prevent oxaliplatin-related hypersensitivity reactions in patients with metastatic colorectal cancer.International journal of clinical oncology · 2026Article
- A real-world study of oxaliplatin-induced hypersensitivity in colorectal cancer treatment based on the pharmacovigilance system in China: a cohort study.Journal of gastrointestinal oncology · 2025Article
- Independent risk and protective factors for oxaliplatin-induced hypersensitivity reactions: a retrospective study.Frontiers in pharmacology · 2025Article
- Misdiagnosis of severe and atypical oxaliplatin‑related hypersensitivity reaction following chemotherapy combined with PD‑1 inhibitor: A case report and literature review.Oncology letters · 2024Article
- Risk of immune system and skin and subcutaneous tissue related adverse events associated with oxaliplatin combined with immune checkpoint inhibitors: a pharmacovigilance study.Frontiers in pharmacology · 2024Article
- Predictors of Hypersensitivity Reactions to Platinum-Based Chemotherapy in a Tertiary Care Hospital in Oman: A case control study.Sultan Qaboos University medical journal · 2023Article
- Oxaliplatin-Related Hypersensitivity Reactions: A Single Institution Series and Literature Review.Biomedicines · 2022Article
- Colon Cancer Pharmacogenetics: A Narrative Review.Pharmacy (Basel, Switzerland) · 2022Review
- Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.American journal of translational research · 2022Article
- Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis.Current medical science · 2021Article
- Safety Profile of Oxaliplatin in 3,687 Patients With Cancer in China: A Post-Marketing Surveillance Study.Frontiers in oncology · 2021Article
- Oxaliplatin-Induced Thrombocytopenia: A Case Report and Review of Pathophysiology of Various Speculative Mechanisms.Cureus · 2020Article
- Nanoallergen platform for detection of platin drug allergies.The Journal of allergy and clinical immunology · 2019Article
- Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.Cancer chemotherapy and pharmacology · 2017Article
- An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activityChemical science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOxaliplatin-based regimens induce a potential risk of hypersensitivity reaction (HSR), with incidence varying from 10% to 25% and lack of clearly identified risk factors. The present study aimed to assess incidence and risk factors in HSR.
methodsAll patients treated with oxaliplatin in the Medical Oncology Department of the Lyon Sud University Hospital (Hospices Civils de Lyon, France) from October 2004 to January 2011 were enrolled. Incidence and severity of HSR were analyzed retrospectively and the potential clinicopathological covariates were tested on univariate and multivariate analysis.
resultsA total of 1,221 doses of oxaliplatin were administered for 191 patients, 8.9% of whom experienced an HSR. Seventeen HSRs were observed, with 1.6% grade 3 and no grade 4 events. The first reaction appeared after a median of 3 oxaliplatin infusions. Using univariate analysis, HSR was associated with younger age (mean age, 56.2 years; p = 0.04), female gender (p = 0.01) and prior exposure to platinum salts (p = 0.02). No increased risk was associated with mean dose or with presence of atopic background. Multivariate analysis confirmed that women were at higher risk of oxaliplatin HSR than men (p < 0.05). Reintroduction of oxaliplatin was effective in 64.7% of hypersensitive patients using an appropriate premedication strategy. Patients who experienced a grade 3 HSR were not rechallenged.
conclusionThe risk of developing oxaliplatin HSR should not be underestimated (8.9% of patients). The medical team's vigilance should be increased with women, younger patients and patients with prior exposure to platinum salts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.